Optiscan has been featured in a Stockhead article, which has also appeared in The Australian and 11 News Corp mastheads, highlighting the company’s accelerated progress in its first-in-human head and neck cancer imaging study and broader momentum across its clinical development program.

The article focuses on the study’s progression to Stage 2 ahead of schedule, following Ethics Committee approval based on the rate, quality and variety of tissues imaged during Stage 1. The next phase will combine in vivo imaging with Optiscan’s InVue during surgery and ex vivo imaging using InForm, with the data expected to support future US FDA submissions, AI development and broader regulatory activities. The report also references the company's breast cancer imaging study at The Royal Melbourne Hospital, which has reached the halfway recruitment milestone.

CEO and Managing Director Dr. Camile Farah said: “It is also helping advance our broader intent to validate the Optiscan platform across multiple tissue types, procedures and healthcare settings.”

Stockhead – Read the full article here.
The Australian – Read the full article here.